Nonalcoholic Fatty Liver Disease and Alcoholic Liver Disease are Major Drivers of Liver Mortality in the United States

被引:55
|
作者
Paik, James M. [1 ]
Golabi, Pegah [1 ]
Biswas, Rakesh [1 ]
Alqahtani, Saleh [2 ]
Venkatesan, Chapy [1 ]
Younossi, Zobair M. [1 ,3 ]
机构
[1] Inova Hlth Syst, Betty & Guy Beatty Ctr Integrated Res, Falls Church, VA USA
[2] Johns Hopkins Univ Hosp, Div Gastroenterol & Hepatol, Baltimore, MD 21287 USA
[3] Inova Fairfax Med Campus, Dept Med, Ctr Liver Dis, 3300 Gallows Rd, Falls Church, VA 22042 USA
关键词
BURDEN; EPIDEMIOLOGY; CONSUMPTION;
D O I
10.1002/hep4.1510
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
In the United States, chronic viral hepatitis B and C (CHB and CHC), nonalcoholic fatty liver disease (NAFLD), and alcohol-related liver disease (ALD) are the main causes of liver deaths attributable to hepatocellular carcinoma (HCC) and cirrhosis. Our aim was to assess the changes in the rates of mortality and years of potential life lost (YLL) for HCC and cirrhosis due to different liver diseases. We used multiple-cause mortality data (2007-2017) from the National Center for Health Statistics. Annual percentage change (APC) in age-standardized death rate per 100,000 (ASDR) and age-standardized years of life lost per 100,000 (ASYLLR) were calculated. In the United States in 2017, there were 2,797,265 deaths with 73,424 liver deaths, contributing to 1,467,742 of YLL. Of the liver deaths, HCC was noted in 12,169 (16.6%) and cirrhosis in 60,111 (82.0%). CHC was responsible for 50.4% of HCC deaths; NAFLD, 35.4%; HBV, 6.0%; ALD, 5.4%; and others, 2.8%. NAFLD was responsible for 48.9% of cirrhosis deaths; ALD, 34.7%; CHC, 12.3%; CHB, 0.9%; and others, 3.2%. Between 2007 and 2017, the increase in ASDR for HCC due to ALD and NAFLD accelerated after 2014 (APC, 11.38% and 6.55%, respectively) whereas CHC stabilized (APC, 0.63%; P = 0.272) after 2011. The increase in ASYLLR of HCC escalated after 2014 for ALD and NAFLD (APC, 12.12% and 6.15%, respectively) and leveled out for CHC after 2012 (APC, -1.05%; P = 0.056). Furthermore, the highest annual increase in ASDR and ASYLLR for cirrhosis was due to ALD (APC, 3.24% and 3.34%, respectively) followed by NAFLD (APC, 1.23% and 0.49%, respectively). Conclusion: Over the past decade, ASDR and ASYLLR due to ALD and NAFLD have been increasing in the United States. The rising burden of HCC and cirrhosis are primarily driven by NAFLD and ALD.
引用
收藏
页码:890 / 903
页数:14
相关论文
共 50 条
  • [31] Hyperuricemia is independently associated with nonalcoholic fatty liver disease in the United States
    Wijarnpreecha, Karn
    Scribani, Melissa
    Thongprayoon, Charat
    Cheungpasitporn, Wisit
    Ungprasert, Patompong
    HEPATOLOGY, 2017, 66 : 1161A - 1162A
  • [32] Alcoholic and Nonalcoholic Fatty Liver Disease and Incident Hospitalization for Liver and Cardiovascular Diseases
    Chang, Yoosoo
    Cho, Juhee
    Cho, Yong Kyun
    Cho, Ara
    Hong, Yun Soo
    Zhao, Di
    Ahn, Jiin
    Sohn, Chong Il
    Shin, Hocheol
    Guallar, Eliseo
    Ryu, Seungho
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2020, 18 (01) : 205 - +
  • [33] PREVALENCE OF NONALCOHOLIC FATTY LIVER DISEASE IN LEAN ADOLESCENTS IN THE UNITED STATES
    Selvakumar, Praveen Kumar Conjeevaram
    Kabbany, Mohammad Nasser
    Lopez, Rocio
    Alkhouri, Naim
    GASTROENTEROLOGY, 2018, 154 (06) : S1217 - S1217
  • [34] Nonalcoholic Fatty Liver Disease After Liver Transplantation for Cryptogenic Cirrhosis or Nonalcoholic Fatty Liver Disease
    Yalamanchili, Kanthi
    Saadeh, Sherif
    Klintmalm, Goeran B.
    Jennings, Linda W.
    Davis, Gary L.
    LIVER TRANSPLANTATION, 2010, 16 (04) : 431 - 439
  • [35] Expand SNAP to Reduce Nonalcoholic Fatty Liver Disease in the United States
    Gundersen, Craig
    JOURNAL OF NUTRITION, 2020, 150 (01): : 6 - 9
  • [36] Oral Diseases Associated with Nonalcoholic Fatty Liver Disease in the United States
    Weintraub, J. A.
    Mitnik, G. Lopez
    Dye, B. A.
    JOURNAL OF DENTAL RESEARCH, 2019, 98 (11) : 1219 - 1226
  • [37] Fatty liver disease: is it nonalcoholic fatty liver disease or obesity-associated fatty liver disease?
    Softic, Samir
    Kahn, C. Ronald
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2019, 31 (01) : 143 - 143
  • [38] Fractionation of gamma-glutamyltransferase in patients with nonalcoholic fatty liver disease and alcoholic liver disease
    Shigeo Sueyoshi
    Setsu Sawai
    Mamoru Satoh
    Masanori Seimiya
    Kazuyuki Sogawa
    Atsushi Fukumura
    Mikihiro Tsutsumi
    Fumio Nomura
    World Journal of Hepatology, 2016, (36) : 1610 - 1616
  • [39] Distinguishing nonalcoholic fatty liver disease from alcoholic liver disease: Is ANI enough? Reply
    Dunn, Winston
    Angulo, Paul
    Sanderson, Schuyler O.
    Kamath, Patrick S.
    Shah, Vrjay
    GASTROENTEROLOGY, 2007, 132 (05) : 2077 - 2078
  • [40] Fractionation of gamma-glutamyltransferase in patients with nonalcoholic fatty liver disease and alcoholic liver disease
    Sueyoshi, Shigeo
    Sawai, Setsu
    Satoh, Mamoru
    Seimiya, Masanori
    Sogawa, Kazuyuki
    Fukumura, Atsushi
    Tsutsumi, Mikihiro
    Nomura, Fumio
    WORLD JOURNAL OF HEPATOLOGY, 2016, 8 (36) : 1610 - 1616